<DOC>
	<DOCNO>NCT02744976</DOCNO>
	<brief_summary>Prediabetes disorder glucose metabolism reflect natural history progression normoglycaemia type 2 diabetes mellitus . Patients prediabetes impaired glucose regulation cause insulin resistance ( IR ) . IR patient undergo percutaneous coronary intervention ( PCI ) associate coronary artery remodel coronary plaque vulnerability intravascular ultrasound ( IVUS ) analysis . In stent restenosis bare metal drug-eluting stent implantation frequently observe patient high fasting-insulin level IR . Although IR significant role progression atherosclerosis prediabetic patient , importance manage prediabetes often under-appreciated clinician . To date , pharmacological treatment officially approve prediabetes . According American Diabetes Association recommendation , metformin drug could consider treatment prediabetic patient high risk develop diabetes . Metformin safe inexpensive glucose lower drug attenuates mortality future cardiovascular event patient type 2 diabetes well progression atherosclerosis non-diabetic animal model . This study design analyze coronary plaque characteristic iMAP IVUS patient without prediabetes undergo PCI evaluate impact metformin treatment coronary plaque characteristic prediabetic patient 24 month follow . The study hypothesis pronounce coronary atherosclerosis progression well in-stent neointimal hyperplasia observe patient prediabetes . Metformin treatment attenuate progression atherosclerosis patient prediabetes .</brief_summary>
	<brief_title>Coronary Artery Disease Progression Patients With Prediabetes</brief_title>
	<detailed_description>Patients undergo PCI IVUS pullback target vessel enrol prospective study . Before PCI 24 month follow fasting blood collect glucose , HbA1c , insulin , C peptide , lipid profile assessment homeostasis model assessment insulin resistance ( HOMA-IR ) calculation . Patients ' baseline demographic characteristic , medical history , procedural data collect index hospitalization 24 month follow . Patients divide group accord HbA1c - control group ( HbA1c &lt; 5.7 ) prediabetic patient ( HbA1c 5.7-6.4 ) . PCI perform accordance guideline . After successful treatment culprit lesion IVUS do . Following PCI IVUS patient prediabetes randomly assign group either receive metformin dose 2000 mg daily plus standard lifestyle recommendation standard lifestyle recommendation . Intravascular ultrasound analysis repeat 24 month initial PCI .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>age â‰¥18 &lt; 75 year ; patient stable coronary artery disease refer PCI artery suitable IVUS pullback ; sign informed consent PCI . cardiac noncardiac illness life expectancy less two year ; failure advance IVUS catheter culprit lesion ; acute coronary syndrome congestive heart failure NYHA IIIIV diabetes mellitus chronic kidney disease previous PCI target vessel heavily calcify vessel allergy metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Prediabetes</keyword>
	<keyword>Intravascular ultrasound</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Metformin</keyword>
</DOC>